Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kisunla
Pharma
Lilly's adjusted Kisunla regimen reduces brain swelling in trial
Eli Lilly looks to tweak the dosing regimen of its Alzheimer’s disease drug Kisunla after showing reduced side effect of brain swelling in a trial.
Kevin Dunleavy
Oct 29, 2024 3:38pm
England's NICE not sold on Lilly's Kisunla despite UK approval
Oct 23, 2024 11:00am
Lilly reveals $1.8B in investments at Irish manufacturing sites
Sep 12, 2024 5:30am
Lawmakers spotlight studies run at China military hospitals
Aug 20, 2024 2:34pm
Eisai and Biogen's Leqembi excels in long-term extension study
Jul 31, 2024 11:05am
Lilly execs chart launch of Alzheimer's newcomer Kisunla
Jul 11, 2024 11:03am
